BioMarin (BMRN) FDA AdCom News for Roctavian 'Extremely Positive' - Truist Securities
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $133.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) saying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
